阿特珠单抗

Atezolizumab

产品编号 :
Cas No. :
包装规格 纯度 目录价 会员专享价 库存 数量

抱歉,暂无牌价信息

晶智化学产品均仅供科研使用。在任何情况下,我们均不提供用于动物或人体用途的产品或服务。

基础信息

CAS No.

1380723-44-3

中文名称

阿特珠单抗

英文名称

Atezolizumab

别名

Atezolizumab;MPDL3280A;Atezolizumab (anti-PD-L1);Research Grade Atezolizumab(DHJ70101);Atezolizumab,Inhibitor,MPDL3280A,inhibit,Apoptosis,Autophagy;Research Grade Atezolizumab;Atezolizumab 58.9mg/ml;Atezolizumab (MPDL3280A)

标准英文名

2-amino-4-((1-(4-amino-3-mercaptophenyl)but-3-en-1-yl)imino)-N-(sec-butyl)-N-(3-methylpentyl)hept-2-enamide--3-ethylidenehex-4-en-2-one--ethane (1/1/1)

分子式

C37H62N4O2S

分子量

627.00

精确分子量

626.46

SMILES

C=CCC(N=C(C=C(N)C(=O)N(CCC(C)CC)C(C)CC)CCC)C1=CC(S)=C(N)C=C1.CC.CC=CC(=CC)C(C)=O

标准SMILES

CC(=O)C(C=CC)=CC.CCCC(C=C(N)C(=O)N(CCC(C)CC)C(C)CC)=NC(CC=C)C1C=CC(N)=C(S)C=1.CC

用途

Atezolizumab is used for the treatment of metastatic urothelial carcinoma that has progressed during or following platinum-containing chemotherapy; it is also approved for first-line treatment of unresectable locally advanced or metastatic PD-L1-positive triple-negative breast cancer (TNBC) in combination with chemotherapy (nab-paclitaxel). Additionally, it is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) that has progressed during or after platinum-based chemotherapy.

InChIKey

MHXMMWFKILDNLC-UHFFFAOYSA-N

安全信息

SureRoute逆合成路线

1.  1380723-44-3 逆合成路线 1

—
—
ACRYTK444
1380723-44-3
来源: SureRoute

2.  1380723-44-3 逆合成路线 2

—
—
—
—
ACRYTK444
1380723-44-3
来源: SureRoute

3.  1380723-44-3 逆合成路线 3

—
—
ACRYTK444
1380723-44-3
来源: SureRoute
评论 0
我是晶智Agent,
您的化学小助手